Sjoerd Hovenga

Drachten, FR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 19, 2026

70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.

70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.

Journal: Breast cancer research and treatment

Published: June 06, 2024

No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status.

No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status.

Journal: Cancer epidemiology

Published: December 16, 2016

The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.

The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.

Journal: European journal of clinical pharmacology

Published: November 30, 2016

Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands.

Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands.

Journal: British journal of haematology

Published: April 11, 2016

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.

Journal: British journal of haematology

Published: April 21, 2015

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome.

Journal: Leukemia & lymphoma

Published: June 06, 2013

Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer.

Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 29, 2011

Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance.

Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance.

Journal: Familial cancer

Published: November 17, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026